J0791 Injection, crizanlizumab-tmca, 5 mg
Billable / valid for submission HCPCS Release 2026Q3
Short description: Inj crizanlizumab-tmca 5mg
Version history
| Release | Valid from | Valid to | Description | Billable |
|---|---|---|---|---|
| 2026Q3 | 2026-07-01 | current | Injection, crizanlizumab-tmca, 5 mg | yes |
Related codes in J07
- J0701 Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg
- J0702 Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
- J0703 Injection, cefepime hydrochloride (b braun), not therapeutically equivalent to maxipime, 500 mg
- J0706 Injection, caffeine citrate, 5 mg
- J0712 Injection, ceftaroline fosamil, 10 mg
- J0713 Injection, ceftazidime, per 500 mg
- J0714 Injection, ceftazidime and avibactam, 0.5 g/0.125 g
- J0716 Injection, centruroides immune f(ab)2, up to 120 milligrams
- J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- J0720 Injection, chloramphenicol sodium succinate, up to 1 gm
- J0725 Injection, chorionic gonadotropin, per 1,000 usp units
- J0735 Injection, clonidine hydrochloride, 1 mg
- J0736 Injection, clindamycin phosphate, 300 mg
- J0737 Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg
- J0738 Injection, lenacapavir, 1 mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
- J0739 Injection, cabotegravir, 1mg, fda approved prescription, only for use as hiv pre-exposure prophylaxis (not for use as treatment for hiv)
- J0740 Injection, cidofovir, 375 mg
- J0741 Injection, cabotegravir and rilpivirine, 2mg/3mg
- J0742 Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg
- J0743 Injection, cilastatin sodium; imipenem, per 250 mg